Improving engineered T cell efficacy for treating solid tumors through epigenetic modulation

The high heterogeneity, lack of tumor-specific targets, and immunosuppressive tumor microenvironment of solid tumors are all significant hurdles for the development of T cell therapies.

Learn how researchers set out to engineer T cells with the objective of introducing small molecule epigenetic inhibitors to assess their impact on T cell cytotoxicity. The research team used the Opera^® Phenix high-content screening system to quantify cytotoxicity and migration of the engineered T-cells. Non-invasive in vivo imaging using the IVIS^® system was then performed in a mouse tumor model to evaluate efficacy of engineered T-cells on tumor burden.

This study demonstrates how epigenetic modulation may be a promising development in improving future cancer immunotherapy for solid tumors.

For research use only. Not for use in diagnostic procedures.